-

Fore Genomics Partners with Inocras to Launch Pediatric Genetic Health Screening and Newborn Sequencing

SAN DIEGO--(BUSINESS WIRE)--Today, Fore Genomics, a leader in pediatric genetic health screening, announced a strategic partnership with Inocras, a leading innovator in whole genome sequencing (WGS) and AI-powered genetic analysis technologies, to enhance Fore’s proprietary pediatric and newborn health screening services.

This collaboration marks a significant step towards improving early detection and intervention for a large number of pediatric-onset genetic conditions, with the initial rollout targeting the U.S. market and subsequent expansion planned for Asian markets.

This partnership will blend Fore’s pediatric screening services with Inocras's cutting-edge whole genome sequencing and bioinformatics platform, providing parents and healthcare providers with precise, personalized, and actionable insights into the genetic health of newborns and children, which can facilitate critical early diagnosis and proactive medical care. Through its CAP-accredited and CLIA-certified lab in San Diego, Inocras provides whole genome sequencing and bioinformatics services for academic and clinical research organizations, as well as pharmaceutical and biotechnology companies, and the company continues to expand its impact through patient-oriented collaborations.

"We are excited to partner with Inocras to bring advanced genetic screening to more families and healthcare providers," said Matthew Pelo, Founder and CEO of Fore Genomics. "Our shared vision of using genomics to improve health outcomes aligns perfectly with this partnership. Together, we aim to set new standards in pediatric genetic screening to make this service available to all families."

“We are excited to partner with Fore Genomics on their pediatric health screening by offering our advanced whole genome sequencing and bioinformatics capabilities,” said Mark Sutherland, Inocras’s Senior Vice President of Business Development. “This partnership will showcase the impactful and actionable genetic insights our whole genome platform delivers. With this provider-ordered test, families can easily collect a sample at home using a simple cheek swab, making the process more accessible and removing barriers to testing.”

Together, Fore Genomics and Inocras are aiming to set a new benchmark in pediatric and newborn sequencing. The partnership underscores both companies' dedication to innovative advancements in the field of genomics and excellence in healthcare.

About Fore Genomics:

Fore Genomics is a leading provider of genetic screening solutions, dedicated to making healthcare more proactive through genetic health screening. Fore’s genetic health screening is designed for newborns, infants and children by reporting on over 600 pediatric-onset conditions and individual response to over 100 medications.

About Inocras:

Inocras is an AI-driven company that specializes in delivering critical insights to cancer and rare disease patients through whole genome sequencing and bioinformatics. The company offers its whole genome testing products, CancerVision and RareVision, and provides research services for pharmaceutical and biotechnology companies as well as research organizations through its CAP/CLIA lab, powered by its proprietary, IP-protected bioinformatics pipeline. Inocras is dedicated to unlocking the potential of whole genome data to enable precision health for everyone. For more information, please visit inocras.com and follow the Inocras LinkedIn page.

Contacts

Media Contact:
Fore Genomics, Inc.
PR Matthew Pelo
Email: info@foregenomics.com

Inocras Inc.
PR Jordan Younis
Email: media@inocras.com

Inocras


Release Versions

Contacts

Media Contact:
Fore Genomics, Inc.
PR Matthew Pelo
Email: info@foregenomics.com

Inocras Inc.
PR Jordan Younis
Email: media@inocras.com

Social Media Profiles
More News From Inocras

Inocras earns ISO 15189 accreditation from ANSI ASQ National Accreditation Board (ANAB)

SAN DIEGO--(BUSINESS WIRE)--ANSI ASQ National Accreditation Board (ANAB) has awarded whole genome sequencing and bioinformatics company, Inocras Inc., accreditation to the ISO 15189 standard under its ISO 15189 Medical Laboratories Accreditation Program. Notably, Inocras is one of very few companies in the world with a CAP/CLIA/ISO 15189 accredited lab performing whole genome sequencing for cancer. This accreditation is based on the International Organization for Standardization (ISO) 15189 Sta...

Inocras and Summit Pharmaceuticals International Corporation Announce Collaboration Aim to Transform Clinical Genomics in Japan

SAN DIEGO--(BUSINESS WIRE)--Inocras Inc. (Head Office: 6330 Nancy Ridge Drive Suite 106
San Diego, CA 92121, President & CEO: Jehee Suh) (“Inocras”) and Summit Pharmaceuticals International Corporation (Head Office: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama) (“SPI”) signed an MOU (Memorandum of understanding) to jointly explore the commercialization of their whole genome sequencing (WGS) analysis services. This collaboration aims to revolutionize healthcare...

Whole Genome MRD Detection with One-in-a-Million LOD: Inocras Launches WGS-Based, Panel-Free MRDVision, Leveraging Ultima ppmSeqTM Technology

SAN DIEGO--(BUSINESS WIRE)--Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of detection (LOD) down to one-in-a-million. MRDVision combines Inocras’s WGS cancer profiling platform, CancerVision, and Ultima Genomics’ ppmSeq™ technology to deliver high-accuracy detection of circulating tumor DNA. This assay offers a low limit of detection, straightforward workflow, and fast turn...
Back to Newsroom